Showing results (21-30 of 35) with videos related to

Sort By:
Pageof 4
Expert Opinion on Drug Delivery|April 13, 2026
Review of the first on-body injector (obi) for the subcutaneous delivery of an oncology drug: isatuximab in multiple myelomaEnrique M Ocio, Gurdeep Parmar, María-Victoria Mateos, et al.
Clinical Lymphoma, Myeloma & Leukemia|October 14, 2023
Progression-Free Survival of Daratumumab Versus Bortezomib Triplet Combination With Lenalidomide and Dexamethasone in Transplant Ineligible Patients With Newly Diagnosed Multiple Myeloma: TAURUS Chart Review StudyLucio Navarro Gordan, Carlyn Rose Tan, Robert Vescio, et al.
The British Journal of Ophthalmology|October 18, 2023
Evaluating the outcome of screening for glaucoma using colour fundus photography-based referral criteria in a teleophthalmology screening programme for diabetic retinopathyRose Tan, Kelvin Yi Chong Teo, Rahat Husain, et al.
Research Square|March 3, 2023
Bortezomib, Lenalidomide and Dexamethasone (VRd) vs Carfilzomib, Lenalidomide and Dexamethasone (KRd) as Induction Therapy in Newly Diagnosed Multiple MyelomaCarlyn Rose Tan, Andriy Derkach, David Nemirovsky, et al.
Blood Cancer Journal|July 25, 2023
Bortezomib, lenalidomide and dexamethasone (VRd) vs carfilzomib, lenalidomide and dexamethasone (KRd) as induction therapy in newly diagnosed multiple myelomaCarlyn Rose Tan, Andriy Derkach, David Nemirovsky, et al.
Research Square|February 26, 2024
Comparison of Infectious Complications with BCMA-directed Therapies in Multiple MyelomaAlexander Lesokhin, Karthik Nath, Tala Shekarkhand, et al.
Future Oncology (London, England)|July 14, 2026
Effectiveness of daratumumab plus bortezomib, lenalidomide, and dexamethasone (DVRd) versus VRd for transplant-eligible newly diagnosed multiple myelomaCarlyn Rose Tan, Lucio Gordan, Joshua Richter, et al.
Blood|May 10, 2024
Antigen escape as a shared mechanism of resistance to BCMA-directed therapies in multiple myelomaRoss S Firestone, Nicholas D Socci, Tala Shekarkhand, et al.
Blood Cancer Journal|May 31, 2024
Comparison of infectious complications with BCMA-directed therapies in multiple myelomaKarthik Nath, Tala Shekarkhand, David Nemirovsky, et al.
Blood Cancer Journal|April 2, 2025
Real-world evaluation of teclistamab for the treatment of relapsed/refractory multiple myeloma (RRMM): an International Myeloma Working Group StudyCarlyn Rose Tan, Sireesha Asoori, Chiung-Yu Huang, et al.
Pageof 4